SELB SELECTA BIOSCIENCES

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that it plans to host a conference call on Thursday, August 4, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10157873. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, .

About Selecta Biosciences, Inc.

Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit .

For Investors:

Bruce Mackle

LifeSci Advisors, LLC



For Media: 

Brittany Leigh, Ph.D.

LifeSci Communications, LLC







EN
28/07/2022

Underlying

SELBSELECTA BIOSCIENCES

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SELECTA BIOSCIENCES

 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces the Appointment of Adrian Bot to Boar...

Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company’s Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science and Technol...

23h / 39m 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Tri...

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis 100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3)  Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) Descartes-08 in SLE patients was observed to have a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy Myositis seamless a...

November 13, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Reports Third Quarter 2025 Financial Results an...

Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected by end of year Approximately $145.1 million cash, cash equivalents and restricted cash as of September 30, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phas...

November 6, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On October 27, 2025, the Company issued to one employee an option to purchase an aggregate of 50,000 shares of the Company’s common stock with an exercise price of $8.85, the closing trading price of the Company’s common stock on the Nasdaq Global Market on ...

October 30, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairm...

Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that Carsten Brunn, Ph.D., was named as Chairman of the Board of Directors, effective October 29, 2025. Dr. Brunn, who currently serves as the Company’s President and Chief Executive Officer and as a member of the Board, will succeed Carrie S. Cox, who is stepping down t...

October 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch